Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | TARBP2 | Q15633 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enoxacin SCHEMBL2635855 | 1.00 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL33963 | 1.00 | LMNA (1.00) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11023659 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL29896709 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL28451325 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL29108687 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11289413 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL28065171 | 0.99 | LMNA (0.98) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL11283102 | 0.95 | LMNA (0.91) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Enoxacin SCHEMBL27515554 | 0.94 | LMNA (0.89) | LMNACYP2C9ATP6V1B2TBXA2REDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319045-A1 | TRANSETHOSOME-ENCAPSULATED AGENTS AND METHODS OF USE THEREOF | UNIV NORTHWESTERN (US) | 2025-10-16 | — | — | US | claimed |
| EP-4017854-B1 | PYRAZINO[1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | CIIMAR CENTRO INTERDISCIPLINAR DE INVESTIG MARINHA E AMBIENTAL (PT) | 2025-08-13 | — | — | EP | claimed |
| EP-4444422-A1 | CATIONIC STEROID COMPOUNDS, METHOD OF OBTAINING THEREOF, FORMULATIONS COMPRISING THEREOF AND THEIR USES | Universidade Do Porto (PT) | 2024-10-16 | — | — | EP | claimed |
| US-20240142377-A1 | DYES UNDERGOING CHANGES IN COLOR AND FLUORESCENCE UPON BINDING OF ORGANIC OXO COMPOUNDS | BUNDESREPUBLIK DEUTSCHLAND, VERTRETEN DURCH DEN BUNDESMINISTER FÜR WIRTSCHAFT UND ENERGIE, DIESER VE (DE) | 2024-05-02 | — | — | US | claimed |
| CN-117334555-A | Immuno-probe type mass spectrum ion source and application thereof | 中国检验检疫科学研究院 | 2024-01-02 | — | — | CN | claimed |
| WO-2023222083-A1 | CONSTIPATION DIAGNOSIS AND TREATMENT | 陕西安宁云生生物技术有限公司 | 2023-11-23 | — | — | WO | claimed |
| EP-4255897-A1 | DYES UNDERGOING CHANGES IN COLOR AND FLUORESCENCE UPON BINDING OF ORGANIC OXO COMPOUNDS | Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Energie, dieser vertreten durch den Präsidenten der (DE) | 2023-10-11 | — | — | EP | claimed |
| CN-116519928-A | Kit for qualitative/quantitative detection of fluoroquinolone compounds and method thereof | 中国检验检疫科学研究院 | 2023-08-01 | — | — | CN | claimed |
| WO-2023105494-A1 | CATIONIC STEROID COMPOUNDS, METHOD OF OBTAINING THEREOF, FORMULATIONS COMPRISING THEREOF AND THEIR USES | UNIVERSIDADE DO PORTO (PT) | 2023-06-15 | — | — | WO | claimed |
| CN-115990463-A | Preparation method and application of modified biomass carbon aerogel for adsorbing antibiotics | 河南工业大学 | 2023-04-21 | — | — | CN | claimed |
| EP-4017854-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental (PT) | 2022-06-29 | — | — | EP | claimed |
| WO-2022122402-A1 | DYES UNDERGOING CHANGES IN COLOR AND FLUORESCENCE UPON BINDING OF ORGANIC OXO COMPOUNDS | BUNDESREPUBLIK DEUTSCHLAND, VERTRETEN DURCH DEN BUNDESMINISTER FÜR WIRTSCHAFT UND ENERGIE, DIESER VERTRETEN DURCH DEN PRÄSIDENTEN DER BUNDESANSTALT FÜR MATERIALFORSCHUNG UND -PRÜFUNG, (BAM) (DE) | 2022-06-16 | — | — | WO | claimed |
| CN-114552974-A | Two-stage DC-DC converter applied to pulse load and control method thereof | 南京理工大学 | 2022-05-27 | — | — | CN | claimed |
| CN-114499247-A | Modulation system and method of cycle conversion type high-frequency link inverter | 南京理工大学 | 2022-05-13 | — | — | CN | claimed |
| CN-121226451-B | Iridium metal complex fluorescent probe for detecting norfloxacin, molecularly imprinted modified iridium probe fluorescent sensor, and preparation method and application thereof | 宁波大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260103703-A1 | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS | ATALANTA THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-112187058-B | Robust stable control method and device of DAB converter | 北京智芯微电子科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-112187057-B | Control method and device for diode clamping hybrid three-level DAB converter | 北京智芯微电子科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-110498806-B | L-threonine-connected dihydroartemisinin-fluoroquinolone conjugate and intermediate, preparation method and application thereof | 西南大学 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319045-A1 | TRANSETHOSOME-ENCAPSULATED AGENTS AND METHODS OF USE THEREOF | LIPA, TTPA, LIPE | LMNA 3303/4885CYP2C9 3424/4885ATP6V1B2 3178/4885 |
| US-20260103703-A1 | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS | SNCA, SYNCRIP, UPF1 | LMNA 538/4885CYP2C9 4880/4885ATP6V1B2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.